logo-loader
viewIXICO PLC

Issue of Equity

/**/ h1{margin-top:24.0pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;line-height:115%;font-size:14.0pt;font-family:"Calibri","sans-serif";color:#31849B;font-weight:bold;}h2{margin-top:10.0pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;line-height:115%;font-size:13.0pt;font-family:"Calibri","sans-serif";color:#31849B;font-weight:bold;}h3{margin-top:12.0pt;margin-right:0cm;margin-bottom:3.0pt;margin-left:0cm;line-height:115%;font-size:13.0pt;font-family:"Calibri Light","sans-serif";font-weight:bold;}h4{margin-top:2.0pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;line-height:115%;font-size:11.0pt;font-family:"Cambria","serif";color:#365F91;font-weight:normal;font-div:italic;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: purple } .as{size:595.3pt 841.9pt;margin:2.0cm 2.0cm 2.0cm 2.0cm;}div.as{}p.bw{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: normal; margin-bottom: 0cm; text-align: right}span.bu{color:black}p.ae,li.ae,div.ae{margin:0cm;margin-bottom:.0001pt;text-align:center;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight:bold;}span.bx{font-family:"Arial","sans-serif";font-size:11.0pt;font-family:"Calibri","sans-serif"}span.br{font-size:11.0pt;color:black}p.by{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: center}p.bz{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; line-height: normal; margin-bottom: 0cm; text-align: center}p.ca{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal} p.cb{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:12.1pt;text-align:justify;line-height: normal}p.cc{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; margin-left: 0cm; margin-right: -12.5pt; margin-top: 0cm; text-align: justify}table.cd{margin-left:-5.4pt;border-collapse:collapse}td.bj{width:286.65pt;padding:0cm 5.4pt 0cm 5.4pt}p.ce{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; margin-bottom: 11.0pt}span.bl{font-size: 10.0pt;line-height:115%;color:black}td.bg{width:142.55pt;padding:0cm 5.4pt 0cm 5.4pt}p.cf{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:11.0pt;text-align:justify}span.bi{font-size:10.0pt;line-height:115%;color:black}p.cg{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt} p.ch{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:11.0pt}span.be{font-size:10.0pt; line-height:115%;color:black}p.ci{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; margin-bottom: 11.0pt; text-align: justify}span.az{font-size:11.0pt;line-height:115%;font-family:"Calibri","sans-serif"}br.ba{page-break-before:always}p.a,li.a,div.a{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";}p.cj{margin-top:0cm;margin-right:0cm;margin-bottom:13.5pt;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify}span.ck{color: black; font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}p.cl{margin-top:0cm;margin-right:0cm;margin-bottom:13.5pt;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin-bottom: 0cm; text-align: justify}span.aw{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black} span.cm{color:black}span.cn{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}span.bs{font-size:11.0pt;font-family:"Calibri","sans-serif"}span.co{color:blue;text-decoration:underline;font-family: "Calibri","sans-serif"; font-size: 11.0pt; text-decoration: none} /**/
RNS Number : 4348K
IXICO plc
28 August 2019
 

28 August 2019

IXICO plc

("IXICO" or the "Company")

 

 Issue of Equity

 

 

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that it has made an application to the London Stock Exchange for the admission to trading on AIM of 37,647 new ordinary shares of 0.1p each ("New Shares") to satisfy the exercise of options.

 

The New Shares are expected to be admitted to trading on AIM on 29 August 2019.

 

 Total voting rights

Application has been made for admission to trading on AIM of 37,647 New Shares. Admission of the New Shares on AIM is expected to become effective at 8.00 a.m. on 29 August 2019, following which there will be in total 46,814,647 ordinary shares in the capital of the Company in issue, each carrying equal voting rights.

 

This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, IXICO under the FCA's Disclosure and Transparency Rules.

 

 

For further information please contact:

 

IXICO plc

+44 (0) 20 3763 7498

Giulio Cerroni, Chief Executive Officer

Grant Nash, Chief Financial Officer




Cenkos Securities PLC (Nominated adviser and sole broker)

+44 (0) 20 7397 8900

Giles Balleny / Max Gould (Corporate Finance)


Michael F Johnson / Russell Kerr (Sales)






 

Optimum Strategic Communications

 +44 (0) 203 950 9144

Mary Clark / Anne Marieke Ezendam / Supriya Mathur


[email protected]


 

About IXICO

 

IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our biopharmaceutical clients' neurological therapeutic pipelines through the application of novel imaging and digital biomarkers.

 

IXICO's data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.

 

More information is available on www.IXICO.com

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
IOELLFFLTIITFIA

Quick facts: IXICO PLC

Price: 66.75

Market: AIM
Market Cap: £31.31 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

IXICO PLC reports first year of profitability 'well ahead of expectations'

IXICO PLC's (LON:IXI) Giulio Cerroni sat down with Proactive London's Andrew Scott after reporting its first year of profitability since its admission to AIM . For the year ended 30 September, the neuroscience analytics firm swung to an underlying (EBITDA) profit of £500,000 from a £600,000...

6 days, 19 hours ago

RNS

PDMR share sale

1 day, 18 hours ago

Holding(s) in Company

1 day, 20 hours ago

PDMR share purchase

1 day, 20 hours ago

Director/PDMR Shareholding

5 days, 19 hours ago

Notice of Results

2 weeks, 5 days ago